Summit Therapeutics Inc vs Vistra Corp — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Vistra Corp trades at $146.7 (market cap $48.64B). The key difference: Vistra Corp is far larger — about 4× Summit Therapeutics Inc's market cap, and Vistra Corp pays a 0.63% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | VST | |
|---|---|---|
Market Cap | $12.06B | $48.64B |
Sector | Health | Technology |
52-Week High | $26.98 | $217.92 |
52-Week Low | $12.55 | $134.71 |
Enterprise Value | $11.39B | $70.58B |
Dividend Yield | — | 0.63% |
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Vistra (VST) trades at $146.68, up 2.67% today, with a bearish technical signal from moving averages but strong analyst support (90.9% buy ratings). Recent Q2 2026 earnings showed a beat on EPS ($2.87 actual vs. $1.32 expected) but a revenue miss, while the company reaffirmed full-year guidance amid growing data center power demand. The stock's valuation includes a P/E of 24.44 and a high ROE of 75.73%, though net cash flow was negative in 2025.
The outlook is positive due to robust EBITDA growth and strategic positioning in the AI power sector, with a consensus price target of $239.75 implying significant upside. Key risks include ERCOT market volatility, hedging losses, and high debt levels, requiring monitoring of execution on data center deals and cost controls.
Trailing returns across standard periods
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →